Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,315
Out of 5,182 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $86.74 | +349.65% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $1.00 | +4,900.00% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $29.40 | +36.05% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $2.37 | +7,073.00% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $6.79 | +194.55% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $25.55 | +95.69% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $201.22 | -28.44% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $86.74
Upside: +349.65%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $1.00
Upside: +4,900.00%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $29.40
Upside: +36.05%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $2.37
Upside: +7,073.00%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $6.79
Upside: +194.55%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $25.55
Upside: +95.69%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $201.22
Upside: -28.44%